CA3129057C - Methode de purification des proteines - Google Patents

Methode de purification des proteines Download PDF

Info

Publication number
CA3129057C
CA3129057C CA3129057A CA3129057A CA3129057C CA 3129057 C CA3129057 C CA 3129057C CA 3129057 A CA3129057 A CA 3129057A CA 3129057 A CA3129057 A CA 3129057A CA 3129057 C CA3129057 C CA 3129057C
Authority
CA
Canada
Prior art keywords
hemopexin
haptoglobin
composition
transferrin
total protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3129057A
Other languages
English (en)
Other versions
CA3129057A1 (fr
Inventor
Nathan Brinkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring AG
Original Assignee
CSL Behring AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/803,525 external-priority patent/US9534029B2/en
Application filed by CSL Behring AG filed Critical CSL Behring AG
Publication of CA3129057A1 publication Critical patent/CA3129057A1/fr
Application granted granted Critical
Publication of CA3129057C publication Critical patent/CA3129057C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4717—Plasma globulins, lactoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, dune manière générale, une méthode de purification des protéines. Plus précisément, il est décrit une méthode de purification de lhaptoglobine et de lhémopexine provenant de la même matière première, et des utilisations associées.
CA3129057A 2012-10-03 2013-10-01 Methode de purification des proteines Active CA3129057C (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261709342P 2012-10-03 2012-10-03
US61/709,342 2012-10-03
US13/803,525 2013-03-14
US13/803,525 US9534029B2 (en) 2012-10-03 2013-03-14 Method of purifying proteins
AU2013203930A AU2013203930B2 (en) 2012-10-03 2013-04-11 A method of purifying proteins
AU2013203930 2013-04-11
EP13170202.9 2013-06-03
EP13170202 2013-06-03
CA2886726A CA2886726C (fr) 2012-10-03 2013-10-01 Methode de purification des proteines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2886726A Division CA2886726C (fr) 2012-10-03 2013-10-01 Methode de purification des proteines

Publications (2)

Publication Number Publication Date
CA3129057A1 CA3129057A1 (fr) 2014-04-10
CA3129057C true CA3129057C (fr) 2023-03-07

Family

ID=52824845

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2886726A Active CA2886726C (fr) 2012-10-03 2013-10-01 Methode de purification des proteines
CA3129057A Active CA3129057C (fr) 2012-10-03 2013-10-01 Methode de purification des proteines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2886726A Active CA2886726C (fr) 2012-10-03 2013-10-01 Methode de purification des proteines

Country Status (8)

Country Link
EP (1) EP2904005A1 (fr)
JP (2) JP6370792B2 (fr)
KR (2) KR102231613B1 (fr)
CN (2) CN104968676A (fr)
CA (2) CA2886726C (fr)
HK (1) HK1212995A1 (fr)
SG (1) SG11201501921SA (fr)
WO (1) WO2014055552A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017025965A1 (fr) 2015-08-13 2017-02-16 Kamada Ltd. Compositions dérivées d'une pâte de fraction de cohn et utilisation desdites compositions
AU2017244763A1 (en) * 2016-03-29 2018-10-18 Kyowa Kirin Co., Ltd. Autoimmune disease therapeutic agent containing, as active ingredient, antibody that binds to haptoglobin in blood to form polyvalent immune complex
US12396943B2 (en) * 2017-08-08 2025-08-26 Csl Behring Ag Hemopexin formulations
ES2982322T3 (es) * 2018-04-18 2024-10-15 Sekisui Medical Co Ltd Método de análisis de hemoglobina
EP3968988A1 (fr) 2019-05-17 2022-03-23 Universität Zürich Haptoglobine destinée à être utilisée dans le traitement d'un évènement neurologique secondaire indésirable suite à un avc hémorragique
US11732004B2 (en) * 2020-04-10 2023-08-22 Plasma Technologies, Llc Compositions and methods for simplified high efficiency isolation of proteins
US20250339492A1 (en) 2021-02-01 2025-11-06 Csl Behring Ag Method of treating or preventing an adverse secondary neurological outcome following a haemorrhagic stroke
WO2022169206A1 (fr) * 2021-02-04 2022-08-11 ㈜Gc녹십자 Procédé de purification d'hémopexine et d'haptoglobine
JP2026502812A (ja) 2022-12-22 2026-01-27 ツェー・エス・エル・ベーリング・アクチエンゲゼルシャフト 混合モードクロマトグラフィーを使用するヘモペキシンの精製方法
CN116179636A (zh) * 2023-01-12 2023-05-30 合肥工业大学 一种血红素和珠蛋白的联产制备方法
WO2025168750A1 (fr) 2024-02-09 2025-08-14 Csl Behring Ag Haptoglobine destinée à être utilisée dans le traitement d'une lésion cérébrale traumatique (tbi)
WO2025257801A1 (fr) 2024-06-13 2025-12-18 CSL Innovation Pty Ltd Protéine de liaison à l'hème pour le traitement d'une lésion d'ischémie-reperfusion (iri)

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1426039A (en) * 1973-11-15 1976-02-25 Green Cross Corp Haptoglobin in aqueous solution and process for tits preparation
JPS5337406B2 (fr) * 1973-11-15 1978-10-09
US4129648A (en) * 1977-11-21 1978-12-12 Collier Harry O J Method for reducing endogenous prostaglandin synthesis
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US4764369A (en) 1983-07-14 1988-08-16 New York Blood Center Inc. Undenatured virus-free biologically active protein derivatives
JPS6317899A (ja) * 1986-07-09 1988-01-25 Green Cross Corp:The ハプトグロビンの精製方法
JPH01305036A (ja) * 1988-05-31 1989-12-08 Green Cross Corp:The 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
US5169936A (en) * 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
US5138034A (en) * 1989-07-12 1992-08-11 The Green Cross Corporation Method of fractionating plasma proteins
FR2672604B1 (fr) * 1991-02-07 1995-05-05 Pasteur Merieux Serums Vacc Procede pour isoler de l'albumine humaine a partir du surnageant iv, notamment iv-4, ou de la fraction v de cohn ou d'un surnageant ou fraction analogue.
SE9301582D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Purification of plasma proteins
DE19830914C1 (de) * 1998-07-10 1999-06-24 Centeon Pharma Gmbh Verfahren zur Herstellung einer Proteinlösung
US6093804A (en) * 1998-09-24 2000-07-25 American National Red Cross Method for purification of alpha-1 proteinase inhibitor
US6815181B2 (en) * 2001-07-09 2004-11-09 Applera Corporation Nucleic acid molecules encoding human secreted hemopexin-related proteins
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
DE10215315A1 (de) * 2002-04-05 2003-11-20 Aventis Behring Gmbh Intellect Human-Transferrin zur Behandlung der Anaemia of Chronic Disease (ACD) und des funktionellen Eisenmangels
AU2002307776A1 (en) * 2002-04-16 2003-10-27 Kamada Ltd. Ultrapure transferrin for pharmaceutical compositions
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
JP2004224793A (ja) * 2003-01-17 2004-08-12 Research Corp Technologies Inc 子宮内膜症の治療方法
JP2004256463A (ja) * 2003-02-26 2004-09-16 Univ Waseda 多形核白血球の細胞接着抑制剤及び細胞接着抑制方法
GB0423196D0 (en) * 2004-10-19 2004-11-24 Nat Blood Authority Method
US7291338B2 (en) * 2005-03-09 2007-11-06 Idexx Laboratories, Inc. Method and device for detecting feline immunodeficiency virus
EP2059818A2 (fr) * 2006-05-15 2009-05-20 Digilab, Inc. Biomarqueurs pour une préforme de diabète de type 2 et méthodes de détection de la présence ou de l'absence d'une préforme du diabète de type 2
WO2009025754A2 (fr) * 2007-08-17 2009-02-26 Csl Behring Gmbh Procédés de purification d'alpha-1-antitrypsine et d'apolipoprotéine a-i
EP2027875A1 (fr) * 2007-08-23 2009-02-25 Octapharma AG Processus d'isolation et de purification d'une protéine cible libre de protéine de prion (PrPSC)
KR101426039B1 (ko) * 2008-09-11 2014-08-01 삼성테크윈 주식회사 얼굴/물체 인식을 위한 특징점 검출 장치 및 방법
FR2942233B1 (fr) * 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
EP2236617A1 (fr) * 2009-03-31 2010-10-06 Leukocare Ag Procédés de stérilisation de terminal de compositions biofonctionnelles
WO2011002070A1 (fr) * 2009-07-02 2011-01-06 協和発酵キリン株式会社 Composition pharmaceutique pour le traitement de troubles ou maladies de surcharge en fer, grâce à laquelle la réduction de concentration en fer est efficace, et qui comprend la protéine gdf7/bmp12
EP2453892B1 (fr) * 2009-07-16 2013-05-29 Institut National de la Santé et de la Recherche Medicale Compositions pharmaceutiques et leur utilisation dans le traitement du cancer
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
PL2464655T3 (pl) * 2009-08-11 2017-08-31 Biocon Limited Procesy chromatograficzne
CN103003422B (zh) * 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
WO2012050874A2 (fr) * 2010-09-28 2012-04-19 Soares Miguel P Ciblage de l'hème pour le traitement de maladies inflammatoires à médiation immunitaire

Also Published As

Publication number Publication date
JP6876655B2 (ja) 2021-05-26
EP2904005A1 (fr) 2015-08-12
JP2015532301A (ja) 2015-11-09
KR20150063547A (ko) 2015-06-09
CN104968676A (zh) 2015-10-07
WO2014055552A1 (fr) 2014-04-10
JP6370792B2 (ja) 2018-08-08
SG11201501921SA (en) 2015-04-29
CA2886726A1 (fr) 2014-04-10
JP2018172426A (ja) 2018-11-08
CN112717125A (zh) 2021-04-30
HK1212995A1 (zh) 2016-06-24
KR102125695B1 (ko) 2020-06-24
CA2886726C (fr) 2021-11-23
KR102231613B1 (ko) 2021-03-25
CA3129057A1 (fr) 2014-04-10
KR20200075027A (ko) 2020-06-25

Similar Documents

Publication Publication Date Title
US10918696B2 (en) Methods of treatment using hemopexin compositions
CA2886726C (fr) Methode de purification des proteines
US6835379B2 (en) Method of producing IgG
CN106414476B (zh) 用于纯化免疫球蛋白的方法
CN106459140B (zh) 用于纯化免疫球蛋白的方法
AU2001273907A1 (en) A method of producing IgG
CA3183021A1 (fr) Procede d'obtention d'une composition comprenant une immunoglobuline m derivee du plasma humain
US20180305401A1 (en) Processes for purifying proteins from plasma
JP7194113B2 (ja) アルブミンの精製方法
CA2584407C (fr) Procede permettant d'isoler l'haptoglobine
HK40050028A (en) A method of purifying proteins
US20220380439A1 (en) Purification of fviii from plasma using silicon oxide adsorption
AU2023409932A1 (en) Method of purifying hemopexin using mixed-mode chromatography

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210826

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250902